Nomdedeu-Sancho Gemma, Gorkun Anastasiya, Mahajan Naresh, Willson Kelsey, Schaaf Cecilia R, Votanopoulos Konstantinos I, Atala Anthony, Soker Shay
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27101, USA.
Wake Forest Organoid Research Center (WFORCE), Winston-Salem, NC 27101, USA.
Cancers (Basel). 2023 Dec 9;15(24):5779. doi: 10.3390/cancers15245779.
Melanoma is responsible for the majority of skin cancer-related fatalities. Immune checkpoint inhibitor (ICI) treatments have revolutionized the management of the disease by significantly increasing patient survival rates. However, a considerable number of tumors treated with these drugs fail to respond or may develop resistance over time. Tumor growth and its response to therapies are critically influenced by the tumor microenvironment (TME); it directly supports cancer cell growth and influences the behavior of surrounding immune cells, which can become tumor-permissive, thereby rendering immunotherapies ineffective. Ex vivo modeling of melanomas and their response to treatment could significantly advance our understanding and predictions of therapy outcomes. Efforts have been directed toward developing reliable models that accurately mimic melanoma in its appropriate tissue environment, including tumor organoids, bioprinted tissue constructs, and microfluidic devices. However, incorporating and modeling the melanoma TME and immune component remains a significant challenge. Here, we review recent literature regarding the generation of in vitro 3D models of normal skin and melanoma and the approaches used to incorporate the immune compartment in such models. We discuss how these constructs could be combined and used to test immunotherapies and elucidate treatment resistance mechanisms. The development of 3D in vitro melanoma models that faithfully replicate the complexity of the TME and its interaction with the immune system will provide us with the technical tools to better understand ICI resistance and increase its efficacy, thereby improving personalized melanoma therapy.
黑色素瘤是导致大多数皮肤癌相关死亡的原因。免疫检查点抑制剂(ICI)疗法通过显著提高患者生存率,彻底改变了该疾病的治疗方式。然而,相当数量接受这些药物治疗的肿瘤无反应或可能随时间产生耐药性。肿瘤生长及其对治疗的反应受到肿瘤微环境(TME)的严重影响;它直接支持癌细胞生长并影响周围免疫细胞的行为,这些免疫细胞可能变得对肿瘤有耐受性,从而使免疫疗法无效。黑色素瘤及其对治疗反应的体外建模可以显著推进我们对治疗结果的理解和预测。人们一直致力于开发可靠的模型,以在合适的组织环境中准确模拟黑色素瘤,包括肿瘤类器官、生物打印组织构建体和微流控装置。然而,整合黑色素瘤TME和免疫成分并进行建模仍然是一项重大挑战。在这里,我们综述了关于正常皮肤和黑色素瘤体外三维模型的生成以及在这些模型中纳入免疫区室所使用方法的近期文献。我们讨论了如何将这些构建体结合起来并用于测试免疫疗法以及阐明治疗耐药机制。忠实复制TME的复杂性及其与免疫系统相互作用的三维体外黑色素瘤模型的开发,将为我们提供技术工具,以更好地理解ICI耐药性并提高其疗效,从而改善个性化黑色素瘤治疗。